Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

"There will not be any research funded by NIH on mRNA vaccines," the scientist in New York similarly told the outlet. "MAGA ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Moderna (NasdaqGS:MRNA) with a Neutral recommendation.

A few years ago, Moderna (NASDAQ: MRNA) stock soared on the back of the highly successful vaccine it developed in record time ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases ...

Scientists say that officials from the National Institutes of Health urged them to remove references to mRNA vaccine ...

Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined BioNTech and Pfizer violated Moderna’s ...

National Institutes of Health officials have urged scientists to remove all references to mRNA vaccine technology from their ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA's Court Victory A German court ruled that BioNTech (BNTX ...

Our valuation report unveils the possibility Moderna's shares may be trading at a premium. NasdaqGS:MRNA Earnings Per Share Growth as at Mar 2025 Searching for a Fresh Perspective? The best AI ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term momentum without new products.